Altre lingue Structure Therapeutics Inc.

Azioni

GPCR

US86366E1064

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 07/02/2025			Variaz. 5gg	Var. 1 gen.
27,40 ^USD	-8,73%		-8,58%	+1,03%

17/12	Structure Therapeutics Inc. - Special Call
17/12	Structure Therapeutics Inc. annuncia la selezione dell'agonista orale di piccole molecole leader del recettore dell'amilina ACCG-2671 per il trattamento dell'obesità	CI

Altre lingue

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences	30/01
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences	30/01
Merck & Co setzt auf neue Abnehmpille - Milliarden-Deal mit Hansoh	18/12
Merck firma acuerdo por hasta 2.000 millones de dólares con la china Hansoh para fármaco contra obesidad	18/12
Structure Therapeutics : Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG 2671 for the Treatment of Obesity Form 8 K	17/12
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity	17/12
Structure Therapeutics Inc. Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity	17/12
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference	18/11
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference	15/11
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference	15/11
Structure Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Highlights Form 8 K	13/11
Structure Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	13/11
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights	13/11
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights	13/11
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity	13/11
Structure Therapeutics Announces First Patients Dosed in Phase 2B ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity	13/11
Viking sube tras los "competitivos" datos de eficacia y seguridad de su píldora para adelgazar	04/11
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024	01/11
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024	31/10/24
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024	31/10/24
Roche comes out against clearing takeover of drug manufacturer Catalent	23/10/24
Sector Update: Health Care Stocks Retreat Late Afternoon	23/09/24
Structure Therapeutics Shares Rise After Morgan Stanley Begins Coverage at Overweight	23/09/24
Structure Therapeutics Names Chief Medical Officer, Chief Development Officer	17/09/24
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer	17/09/24

Iscriviti per accedere a più notizie

Registrazione 100% gratuita

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Structure Therapeutics Inc.

Azioni

GPCR

US86366E1064

Biotecnologia

Altre lingue

Filtri